2. Search Result
Search Result
Results for "

somatostatin analogue

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

22

Peptides

3

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1959
    Lanreotide

    BIM 23014

    		 Somatostatin Receptor Endocrinology Cancer
    Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome .
    Lanreotide
  • HY-P1959A
    Lanreotide acetate

    BIM 23014 acetate

    		 Somatostatin Receptor Endocrinology Cancer
    Lanreotide (BIM 23014) acetate is a somatostatin analogue with antineoplastic activity. Lanreotide acetate can be used for the research of carcinoid syndrome .
    Lanreotide acetate
  • HY-P3314
    Nendratareotide

    		Somatostatin Receptor Metabolic Disease
    Nendratareotide is a somatostatin analogue .
    Nendratareotide
  • HY-P10920
    DOTAMTATE

    		Drug Derivative Cancer
    DOTAMTATE is a somatostatin analogue. DOTAMTATE marked 212Pb is promising for research of somatostatin receptor positive neuroendocrine tumors .
    DOTAMTATE
  • HY-123460
    BN-81674

    		Somatostatin Receptor Cancer
    BN-81674 is a somatostatin analogue and a selective antagonist of the non-peptide human somatostatin sst3 receptor (Ki=0.92 nM). In addition, BN-81674 reversed the inhibition of cyclic AMP accumulation induced by 1 nM somatostatin through the sst3 receptor with an IC50 value of 0.84 nM. BN-81674 can be used in cancer research .
    BN-81674
  • HY-P3897
    [Tyr12] Somatostatin 28 (1-14)

    		Somatostatin Receptor Neurological Disease
    [Tyr12] Somatostatin 28 (1-14) is an analogue of Somatostatin-28 (1-14) (HY-P1499). Somatostatin-28 (1-14) is an N-terminal fragment of the neuropeptide somatostatin-28 .
    [Tyr12] Somatostatin 28 (1-14)
  • HY-P3903
    [D-Trp8,Tyr11] Somatostatin

    		Somatostatin Receptor Endocrinology
    [D-Trp8,Tyr11] Somatostatin is an analogue of somatostatin. Somatostatin is a hormone that regulates a variety of bodily functions. DTrp8 residue can increase stability .
    [D-Trp8,Tyr11] Somatostatin
  • HY-P3952
    (D-Trp8,D-Cys14)-Somatostatin-14

    		Somatostatin Receptor Metabolic Disease
    (D-Trp8,D-Cys14)-Somatostatin-14 is a Somatostatin synthetic analogue. (D-Trp8,D-Cys14)-Somatostatin-14 can be used for the research of metabolic related diseases .
    (D-Trp8,D-Cys14)-Somatostatin-14
  • HY-P4957
    Octreotide dimer (parallel)

    		Somatostatin Receptor Others
    Octreotide dimer parallel is a dimer parallel of Octreotide. Octreotide (HY-P0036) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue .
    Octreotide dimer (parallel)
  • HY-P3953
    Wy 41747

    		Somatostatin Receptor Metabolic Disease
    Wy 41747 is a long-acting Somatostatin analogue. Wy 41747 can be used for the research of diabetes mellitus .
    Wy 41747
  • HY-P1959B
    Lanreotide diTFA

    BIM 23014 diTFA

    		 Somatostatin Receptor Endocrinology Cancer
    Lanreotide (BIM 23014) diTFA is a somatostatin analogue with antineoplastic activity. Lanreotide diTFA can be used for the research of carcinoid syndrome .
    Lanreotide diTFA
  • HY-P0024
    Veldoreotide

    DG3173; PTR-3173

    		 Somatostatin Receptor Endocrinology Cancer
    Veldoreotide (DG3173) a somatostatin analogue, binds to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide inhibits growth hormone (GH) secretion in adenomas compared with Octreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent
    Veldoreotide
  • HY-P0036B
    Octreotide pamoate

    SMS 201-995 pamoate

    		 Somatostatin Receptor Apoptosis Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Octreotide (SMS 201-995) pamoate is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide pamoate can bind to the somatostatin receptors which are mainly subtypes 2, 3 and 5. Octreotide pamoate increases Gi activity and reduces intracellular cAMP production. Octreotide pamoate has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .
    Octreotide pamoate
  • HY-P0036
    Octreotide
    Maximum Cited Publications
    13 Publications Verification

    SMS 201-995

    		 Somatostatin Receptor Apoptosis Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .
    Octreotide
  • HY-P0024A
    Veldoreotide TFA

    DG3173 TFA; PTR-3173 TFA

    		 Somatostatin Receptor Endocrinology Cancer
    Veldoreotide (DG3173) TFA a somatostatin analogue, binds to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide TFA inhibits growth hormone (GH) secretion in adenomas compared with Octreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent
    Veldoreotide TFA
  • HY-79135
    Pasireotide ditrifluoroacetate
    5+ Cited Publications

    SOM230 ditrifluoroacetate; Pasireotide TFA salt

    		 Somatostatin Receptor Endocrinology Cancer
    Pasireotide (SOM230) ditrifluoroacetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide ditrifluoroacetate exhibits antisecretory, antiproliferative, and proapoptotic activity .
    Pasireotide ditrifluoroacetate
  • HY-16381B
    Pasireotide (diaspartate)

    SOM230 (diaspartate)

    		 Somatostatin Receptor Neurological Disease Cancer
    Pasireotide (SOM230) diaspartate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide diaspartate exhibits antisecretory, antiproliferative, and proapoptotic activity .
    Pasireotide (diaspartate)
  • HY-108768
    Pasireotide pamoate

    SOM230 pamoate

    		 Somatostatin Receptor Endocrinology Cancer
    Pasireotide (SOM230) pamoate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide pamoate exhibits antisecretory, antiproliferative, and proapoptotic activity .
    Pasireotide pamoate
  • HY-P0036S4
    Octreotide-d8 acetate

    SMS 201-995-d8 acetate

    		 Isotope-Labeled Compounds Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Octreotide-d8 (acetate) (SMS 201-995-d8 (acetate)) is deuterium labeled Octreotide. Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .
    Octreotide-d8 acetate
  • HY-P0036S2
    Octreotide-d8

    SMS 201-995-d8

    		 Isotope-Labeled Compounds Apoptosis Somatostatin Receptor Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Octreotide-d8 (SMS 201-995-d8) is deuterium labeled Octreotide. Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .
    Octreotide-d8
  • HY-79136
    Pasireotide L-aspartate salt
    5+ Cited Publications

    SOM230 L-aspartate

    		 Somatostatin Receptor Endocrinology Cancer
    Pasireotide (SOM230) L-aspartate salt, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide L-aspartate salt exhibits antisecretory, antiproliferative, and proapoptotic activity .
    Pasireotide L-aspartate salt
  • HY-P0036S3
    Octreotide-13C9,15N

    SMS 201-995-13C9，15N

    		 Isotope-Labeled Compounds Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Octreotide- 13C9, 15N (SMS 201-995- 13C9, 15N) is 13C and 15N labeled Octreotide. Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .
    Octreotide-13C9,15N
  • HY-16381A
    Pasireotide acetate
    2 Publications Verification

    SOM230 acetate

    		 Somatostatin Receptor Endocrinology Cancer
    Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity .
    Pasireotide acetate
  • HY-16381
    Pasireotide
    5+ Cited Publications

    SOM230

    		 Somatostatin Receptor Endocrinology Cancer
    Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity .
    Pasireotide
  • HY-103277A
    BIM 23042 TFA

    		Bombesin Receptor Neurological Disease Metabolic Disease
    BIM 23042 TFA, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin B (HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca 2+ release .
    BIM 23042 TFA
  • HY-103277
    BIM 23042

    		Bombesin Receptor Neurological Disease Metabolic Disease
    BIM 23042, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin B (HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca 2+ release .
    BIM 23042
  • HY-P2090
    Angiopeptin

    		Somatostatin Receptor Adenylate Cyclase Cardiovascular Disease
    Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak sst2/sst5 receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin has the potential for coronary atherosclerosis research .
    Angiopeptin
  • HY-P2090A
    Angiopeptin TFA

    		Somatostatin Receptor Adenylate Cyclase Cardiovascular Disease
    Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak sst2/sst5 receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research .
    Angiopeptin TFA
  • HY-105172A
    TT-232 TFA

    CAP-232 TFA; TLN-232 TFA

    		 Somatostatin Receptor Apoptosis Cancer
    TT-232 TFA (CAP-232 TFA) is an analogue of somatostatin. TT-232 TFA can induce apoptosis of pancreatic tumor cell lines, inhibit tyrosine kinase activity and stimulate tyrosine phosphatase activity in colon tumor cell lines. TT-232 TFA inhibits the proliferation of tumor cells, induces apoptosis of tumor cells and shows strong anti-tumor effects. TT-232 TFA can be used in the development of anti-tumor drugs and the study of apoptosis mechanism .
    TT-232 TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: